KMID : 1128320220200020039
|
|
Electrolytes & Blood Pressure 2022 Volume.20 No. 2 p.39 ~ p.48
|
|
Blood Pressure Control in Patients with Diabetic Kidney Disease
|
|
Kim Yae-Ni
Kim Won Kim Jwa-Kyung Moon Ju-Young Park Samel Fei Jiang Park Hoon-Suk Song Sang-Heon Yoo Tae-Hyun Lee So-Young Lee Eun-Young Kim Chul-Min Jin Kyu-Bok Cha Dae-Ryong Cha Jin-Joo Han Sang-Youb
|
|
Abstract
|
|
|
Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease.
Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested the implementation of a more intensive BP control with a target systolic BP (SBP) of <120 mmHg based on the evidence that the CV benefits obtained is outweighed by the kidney injury risk associated with a lower BP target. However, an extremely low BP level may paradoxically aggravate renal function and CV outcomes. Herein, we aimed to review the existing literature regarding optimal BP control using medications for DKD.
|
|
KEYWORD
|
|
Blood pressure, Diabetes, Kidney, Mortality
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|